But Caution Author: Steven Benowitz
The human genome has become extremely big business.
IN DEVELOPMENT: Myriad CEO Peter Meldrum sees increasing industry-academia ties in genetics
Myriad Genetics Inc., a genetic testing company in Salt Lake City, Utah, recently announced it would begin offering large-scale testing to detect a mutated gene for inherited breast cancer, BRCA1. Myriad, which owns the patent for the gene, has spent some $7 million to isolate and characterize it, and has licensed the therapeutic rights to Eli Lilly and Co. of Indianapolis for an undisclosed amount. Another company, OncorMed-a subsidiary of...